Orelabrutinib
Orelabrutinib (ICP-022) is a potent, orally bioavailable, and irreversible small molecule inhibitor targeting Bruton's tyrosine kinase (BTK) . It is widely used in preclinical research for studying B-cell malignancies and autoimmune diseases, demonstrating efficacy in both in vitro cellular assays and in vivo animal models.
Product Specifications
CAS Number
1655504-04-3
Product Name Alternative
Lymphocytic leukemia, Orelabrutinib, inhibit, Inhibitor, ICP 022, ICP022, ICP-022, Malignancies, cell, chronic, antineoplastic, Bruton tyrosine kinase, Btk, BTK, small
Field of Research
Cardiovascular Research, Signal Transduction
Purity
97.77% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.68 mM) ; DMSO:55 mg/mL (128.66 mM)
Smiles
NC (=O) c1ccc (nc1-c1ccc (Oc2ccccc2) cc1) C1CCN (CC1) C (=O) C=C
Molecular Formula
C26H25N3O3
Molecular Weight
427.49
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![9-oxo-6,9-dihydro-7H-pyrano[4,3-e]pyrazolo[1,5-a]pyrimidine-3-carbonitrile](https://cdn.genprice.uk/genprice/uk/genprice3.webp)
sc-351676A 1 g
9-oxo-6,9-dihydro-7H-pyrano[4,3-e]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
Sign In for Pricing
View Details 
